LAVAL, Quebec, Jan. 10, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX andTSX: VRX) ("Valeant" or the "Company") wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced the expanded parameter range for Bausch + Lomb ULTRA® for Presbyopia contact lenses. Since the contact lenses first launched in February 2016, Bausch + Lomb ULTRA® for Presbyopia contact lenses have been available in parameters between -7 D to +2 D. The expansion now extends the power range available to eye care professionals and patients to +4.50D to -10.00D (in 0.25D steps) in both low add and high add.
Bausch + Lomb ULTRA® for Presbyopia contact lenses, monthly replacement silicone hydrogel lenses, combine the company's innovative MoistureSeal® technology, which delivers exceptional end-of-day comfort1, with the proven 3-Zone Progressive™ design also found in Biotrue® ONEday for Presbyopia daily disposable contact lenses. The combination of these advanced proprietary technologies provides presbyopic patients exceptional comfort and outstanding vision at near, intermediate, and distance.1,3
"The Bausch + Lomb ULTRA® for Presbyopia contact lenses are providing eye care professionals a multifocal lens option that delivers exceptional comfort and the clarity of vision their presbyopic patients need," said Joe Papa, Chairman and Chief Executive Officer of Valeant. "This is just one example of our continued commitment to providing outstanding innovations that meet the needs of our customers and their patients."
For more information regarding the expanded parameters for the Bausch + Lomb ULTRA® for Presbyopia contact lenses, visit the Newsroom section at www.bausch.com
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
1. Data on file. Bausch & Lomb Incorporated. Rochester, NY; 2015.
2. Thirty-nine ECPs (from 10 countries) refitted 441 existing soft contact lens wearing presbyopesinto PureVision®2 Presbyopia lenses. Patients returned for follow-up.
3. Results of an online survey with habitual presbyopic contact lens wearers who wore their lenses for approximately 5 days (n=181). Survey questions were top 3-box scores (% Strongly Agree, Agree, Slightly Agree) on a 6-point agreement scale.
Bausch + Lomb ULTRA, MoistureSeal, Biotrue, 3-Zone Progressive and PureVision are trademarks of Bausch & Lomb Incorporated.
877-281-6642 (toll free)
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
SOURCE Valeant Pharmaceuticals International, Inc.